Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline
Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.
Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.
What's Your Reaction?
